Hanson Pharmaceuticals announced on the Hong Kong Stock Exchange that the group's self-developed tyrosine kinase 2 selective allosteric inhibitor HS-10374 has reached common major endpoints in critical phase III clinical trials for moderate to severe plaque psoriasis in adults.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.